Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T23:08:27.775Z Has data issue: false hasContentIssue false

Evaluating and improving the quality of risperidone prescribing

Published online by Cambridge University Press:  02 January 2018

David Taylor*
Affiliation:
Bethlem and Maudsley NHS Trust, London SE5 8AZ
Robert Holmes
Affiliation:
Royal London Hospital (Mile End), Bancroft Road, London E1 4DG
Trudi Hilton
Affiliation:
Ealing Hospital Uxbridge Road, Middlesex UB1 3HW
Carol Paton
Affiliation:
Bexley Hospital Old Bexley Lane, Bexley DA5 2BW
*
∗ Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Clinical studies suggest that risperidone is an effective antipsychotic with a low incidence of extrapyramidal adverse effects. In a prescription survey of several trusts, we found that risperidone was widely prescribed at high doses alongside typical neuroleptics and anticholinergic drugs. We also demonstrated that prescribing in a single trust can be improved by simple interventions. Risperidone should be prescribed as the sole antipsychotic at doses below 8 mg/day to realise fully its clinical advantages. Few prescriptions met this standard.

Information

Type
Original Papers
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists
Submit a response

eLetters

No eLetters have been published for this article.